SimPharma is an early stage biopharma company based in Singapore. We are developing DAA-I, a potentially revolutionary new treatment for inflammation-linked diseases.
News on DAA-I
Interview on Channel NewsAsia (Nov 2016): Defeating Diabetes - An oral anti-diabetic drug that could change the way diabetes is treated and a milestone for research in Singapore. [Link no longer active]
Article on AsiaOne (Oct 2016): NUS medicine researchers develop oral-anti-diabetic drug. [Link no longer active. Archive version]
Article on BioSpectrum Asia (Oct 2016): Singapore develops oral-anti-diabetic drug. [Link no longer active. Archive version]
Article on Zao Bao SG (Oct 2016): 有助延缓病情恶化 “新加坡制造”抗糖尿病药料三年后面市.
Selected publications on DAA-I
Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects (Nov 2017). See PubMed entry
A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-Aspartate Angiotensin I in Healthy Subjects (Sep 2016). See PubMed entry
Des-aspartate-angiotensin I causes specific release of PGE2 and PGI2 in HUVEC via the angiotensin AT1 receptor and biased agonism (Dec 2015). See PubMed entry
Des-Aspartate-Angiotensin I Attenuates Mortality of Mice Exposed to Gamma Radiation via a Novel Mechanism of Action (Sep 2015). See PubMed entry
Des-Aspartate-Angiotensin I, a Novel Angiotensin AT(1) Receptor Drug (Apr 2015). See PubMed entry
Des-aspartate-angiotensin-I and angiotensin IV improve glucose tolerance and insulin signalling in diet-induced hyperglycaemic mice (Nov 2011). See PubMed entry
Effects of des-aspartate-angiotensin I on myocardial ischemia-reperfusion injury in rats (May 2011). See PubMed entry
Des-aspartate-angiotensin I exerts hypoglycemic action via glucose transporter-4 translocation in type 2 diabetic KKAy mice and GK rats (Dec 2007). See PubMed entry
Cardioprotective effect of des-Aspartate-angiotensin-I (DAA-I) on cytokine gene expression profile in ligation model of myocardial infarction (Feb 2006). See PubMed entry
Reduction of infarct size by orally administered des-aspartate-angiotensin I in the ischemic reperfused rat heart (Aug 2004). See PubMed entry
Effects of des-aspartate-angiotensin I on neointima growth and cardiovascular hypertrophy (Mar 2004). See PubMed entry
Effects of des-Asp-angiotensin I on experimentally-induced cardiac hypertrophy in rats (Feb 1998). See PubMed entry
For other publications on DAA-I please contact SimPharma here.